

IN THE CLAIMS

1. (Amended) A method for inhibiting the adherence of lymphocytes to endothelial cells comprising exposing the lymphocytes to an effective amount of an antibody, or [a fragment or derivative] an antigen-binding region thereof, that binds to $\alpha 4\beta 1$.
 32. (Amended) A method of preventing lymphocyte migration into tissues comprising administering an effective amount of an antibody, or [a fragment or derivative] an antigen-binding region thereof, which prevents the adhesion of lymphocytes to endothelial cells via an [extracellular matrix] $\alpha 4\beta 1$ receptor to a subject in need of such treatment.

~~Cancel claim 33 without prejudice.~~

REMARKS

Applicant has amended the specification to make explicit applicant's claim of priority from copending application Serial No. 07/402,489, filed September 1, 1989, now abandoned. The Examiner correctly notes that reference to application Serial No. 07/402,389 appears in the oath in this application. Thus, the omission of a statement in the specification claiming continuation-in-part status was inadvertent.

Applicant notes the Examiner's reference to deficiencies in the formal drawings and photographs previously submitted. Applicant will file corrected formal drawings and photographs in response to a Notice of Allowability, pursuant to 37 C.F.R. § 1.85(c).

The Examiner objects to the specification as containing various typographical errors and as failing to comply with 37 C.F.R. § 1.821(d). Applicant has amended the